XTRA:FREHealthcare
Assessing Fresenius SE KGaA (XTRA:FRE) Valuation After New Cell Therapy Agreement With TQ Therapeutics
Fresenius SE KGaA (XTRA:FRE) is drawing fresh attention after Fresenius Kabi agreed an exclusive cell selection technology license with TQ Therapeutics, targeting wider access to cell and gene therapies and potential expansion of its treatment toolkit.
See our latest analysis for Fresenius SE KGaA.
The collaboration around cell and gene therapies comes as Fresenius SE KGaA’s €51.98 share price sits on a 10.10% 3 month share price return and a 50.36% 1 year total shareholder return. This...